The global Human Papillomavirus (HPV) Vaccine Market, valued at US$ 4.0 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 9.4% from 2023 to 2031, reaching US$ 9.1 billion by 2031. HPV vaccines, such as Gardasil and Cervarix, prevent infections linked to cervical cancer, genital warts, and other HPV-related diseases. The market is driven by increasing cervical...